

**Angiogenesis, Metastasis, and the Cellular Microenvironment****Sprouty-4 Inhibits Transformed Cell Growth, Migration and Invasion, and Epithelial-Mesenchymal Transition, and Is Regulated by Wnt7A through PPAR $\gamma$  in Non-Small Cell Lung Cancer**Meredith A. Tennis<sup>1</sup>, Michelle M. Van Scoyk<sup>1</sup>, Scott V. Freeman<sup>1</sup>, Katherine M. Vandervest<sup>1</sup>, Raphael A. Nemenoff<sup>1</sup>, and Robert A. Winn<sup>1,2</sup>**Abstract**

Sprouty proteins are potent receptor tyrosine kinase inhibitors that antagonize growth factor signaling and are involved in lung development. However, little is known about the regulation or targets of Sprouty-4 (Spry4) in lung cancer. Our study aimed to determine the role of Spry4 in non-small cell lung cancer (NSCLC). We found that Spry4 mRNA expression was decreased in NSCLC cell lines and in dysplastic lung cell lines compared with a nontransformed cell line, suggesting that Spry4 has tumor-suppressing activity. When Spry4 was stably transfected into H157 and H2122 NSCLC cell lines, decreased migration and invasion were observed. Matrix metalloproteinase-9 activity was decreased, and the expression of matrix metalloproteinase inhibitors TIMP1 and CD82 were increased. Stable expression of Spry4 led to reduced cell growth and reduced anchorage-independent growth in NSCLC cell lines, along with upregulation of tumor suppressors p53 and p21. Changes in epithelial and mesenchymal markers indicated that Spry4 expression induces a reversal of the epithelial to mesenchymal transition characteristic of tumor cells. Treatment of a nontransformed lung epithelial cell line with short hairpin RNA to Spry4 led to the decreased expression of epithelial markers and increased cell growth, supporting the concept of Spry4 acting as a tumor suppressor. We showed that the activity of the Spry4 promoter is increased by Wnt7A/Fzd9 signaling through peroxisome proliferator-activated receptor  $\gamma$ . These data present previously undescribed targets of Spry4 and suggest that Spry4 is a downstream target of Wnt7A/Fzd9 signaling. Spry4 may have efficacy in the treatment of NSCLC. *Mol Cancer Res*; 8(6); 833–43. ©2010 AACR.

**Introduction**

Sprouty (Spry) proteins were first identified as potent receptor tyrosine kinase (RTK) inhibitors that modulate tracheal branching in *Drosophila* (1, 2). Subsequent studies identified four vertebrate Spry proteins with highly conserved COOH-terminal and Spry domains, and variable NH<sub>2</sub>-terminal domains (3). The interaction of Spry proteins with RTK pathways depends on the specific Spry and cellular context. Sprys have been shown to inhibit epidermal growth factor (EGF) receptor, fibroblast growth factor (FGF) receptor, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor (4–6). Sprys can bind to growth factor receptor binding protein 2 or son of sevenless homolog 1 (SOS) to disrupt the

receptor complex and interfere with extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) activation. Spry2 has been shown to interact with c-CBL to inhibit EGF-mediated ERK/MAPK signaling (3). Downregulation of Spry1 has been observed in breast and prostate cancer; of Spry2 in breast, prostate, and liver cancer; and of Spry4 in prostate cancer (7, 8). Spry4 seems to act as a marker of treatment response in gastrointestinal tumors, and Spry1 presence is associated with a good prognosis in renal cell carcinoma patients (8). A protective role for Spry2 in the lung has been described *in vitro*, as well as *in vivo* in a urethane model of non-small cell lung cancer (NSCLC) and in a germline KRAS mutation model of lung cancer (9–11).

The Wnt family of proteins control diverse developmental pathways and act in cooperation with the Frizzled (Fzd) family of seven-membrane spanning G-coupled protein receptors. Increased activity of the canonical Wnt/ $\beta$ -catenin signaling pathway has been associated with oncogenic stimulation in several types of cancer (12–16). In contrast, our previous work has shown Wnt7A is lost in NSCLC and activation of Wnt7A signaling leads to the reversal of the transformed phenotype in NSCLC (17). Wnt7A binds to the Fzd9 receptor and signals through ERK-5

**Authors' Affiliations:** <sup>1</sup>University of Colorado Denver and <sup>2</sup>Veterans Affairs Medical Center, Denver, Colorado

**Corresponding Author:** Meredith Tennis, University of Colorado at Denver and Health Sciences Center, 12700 East 19th Avenue, Box C272, RC2 9th Floor, Aurora, CO 80045. Phone: 303-724-6093; Fax: 303-724-6042. E-mail: Meredith.tennis@ucdenver.edu

doi: 10.1158/1541-7786.MCR-09-0400

©2010 American Association for Cancer Research.

to activate the tumor suppressor peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ), but the downstream targets of PPAR $\gamma$  are largely unknown (18, 19). PPAR $\gamma$  and its synthetic agonists, such as ciglitazone and rosiglitazone, inhibit transformed growth and metastasis, promote epithelial differentiation, and have shown tumor prevention efficacy (20-25).

We previously observed that Spry4 expression is upregulated with the activation of Wnt7A and Fzd9 by quantitative PCR (QPCR) and immunoblot in NSCLC, suggesting a role for Spry4 in a pathway outside of RTK signaling (17). However, the specific involvement of Spry4 in this noncanonical Wnt signaling pathway is unknown. Spry4 has been shown to inhibit FGF pathways in cell lines and mice, but unlike other members of the Spry family, Spry4 has not been shown to inhibit EGF signaling (5, 26, 27). Evaluation of mouse organogenesis has identified Spry4 expression in the lung epithelium of the developing embryo, but characterization of Spry4 expression in adult lung tissue still needs to be completed (28). There is clearly a need for further studies exploring the role of Spry4 in the context of the lung epithelium. In the study presented here, we examined Spry4 activity in NSCLC and found that it is lost in cancer cell lines and dysplastic cell lines. We identified Wnt7A/Fzd9 and PPAR $\gamma$  as regulators of Spry4 and described new targets of Spry4 known to be involved in suppressing tumor growth and metastasis. We showed that the reexpression of Spry4 results in decreased transformed cell growth, decreased migration and invasion, and increased differentiation of NSCLC cells.

## Materials and Methods

### Cell culture and retrovirus-mediated gene transfer

NSCLC and Beas2B (a human nontransformed lung epithelial cell line) cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum at 37°C in a humidified 5% CO<sub>2</sub> incubator. The human bronchial epithelial cell (HBEC) cell line was cultured in Bronchial Epithelial Basal Media at 37°C in a humidified 5% CO<sub>2</sub> incubator. Cell lines were obtained from the University of Colorado Cancer Center Cell Line Core in 1995, except the HBEC cell line, which was obtained in 2009 from Dr. Robert Doebele at the University of Colorado Denver, Denver, CO. Morphology of all cell lines was monitored twice weekly, and stocks of cell lines were passaged no >10 times for use in experiments. The *Spry4*/PCDNA3 vector was kindly provided by Diane Harris (University of California at Los Angeles, Los Angeles, CA). *Spry4* was ligated into the retroviral vector LPCX (Clontech), and 3  $\mu$ g of the expression vector with *Spry4* was packaged into a replication-defective retrovirus using 293t cells as previously described (17). H157 and H2122 cell lines were transduced, selected, and maintained in growth medium containing puromycin (1  $\mu$ g/mL). The H157 Wnt7A/Fzd9 cell line was previously described (17). The B2B *Spry4* knockdown cell lines were created using *Spry4* short hairpin RNA (shRNA) in a lentiviral vector from Open Biosystems.

293t cells were transfected with packaging vectors and 1  $\mu$ g of the *Spry4* lentiviral shRNA or negative lentiviral control plasmid, and then B2B cells were transduced with the resulting viral media. Cell lines were selected and maintained with growth medium containing puromycin (1  $\mu$ g/mL).

### Cell growth, MTS assay, soft agar assay, and caspase assay

For the cell growth assay, 50,000 cells were seeded in triplicate per well of a 24-well culture plate in complete growth medium. Cells were counted for 6 days using a hemocytometer. For the soft agar assay, 2,500 cells were seeded in triplicate in a six-well plate and the assay was conducted as previously described (18). The data are presented as cloning efficiency: the mean number of colonies per well divided by the number of cells plated. Activity of caspase-3/7 was analyzed using a Caspase-Glo 3/7 Assay (Promega). For the MTS assay (Promega), 500 cells per well were seeded in triplicate for each cell line. At 24, 48, and 72 hours, 20  $\mu$ L of MTS reagent was added to each well, incubated for 1 hour at 37°C, and the results analyzed in a 96-well plate reader at 490 nm. The sample data were normalized to background readings of media only.

### Quantitative real-time PCR

RNA was extracted from cells with RNeasy (Qiagen, Inc.), and 5  $\mu$ g of RNA were converted to cDNA. RNA from primary dysplastic cell cultures was a gift from Dr. Dan Merrick (Veterans Affairs Medical Center, Denver, CO). Dysplastic cell cultures are arbitrarily numbered 1 to 13. Primer sequences for *Spry4* were F 5'-CCAG-GATGTCACCCAC CATTG-3' and R 5'-TGTGCTGC-TGCTGCTC-3', and F 5'-GCCAAATATG ATGACAT-CAAGAAGG-3' and R-5'GGTGTCGCTGTTGAAGT-CAGAG-3' for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Integrated DNA Technologies). Primer sets for p53, p21, CD82, TIMP1, KRT8, KRT18, and Vimentin were obtained from SABiosciences and are available on the manufacturer's Web site (SABioscience). PCR conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. *Spry4* and GAPDH reactions included 2  $\mu$ L of cDNA, SYBRGreen Jumpstart Taq Readymix (Sigma Aldrich), 200 nmol/L primers, and 2 mmol/L MgCl<sub>2</sub> in a 25- $\mu$ L volume. Superarray PCR required the RT<sup>2</sup> Real-time SYBRGreen PCR Master Mix (SABioscience) and 1  $\mu$ L of Superarray qRT-PCR Primer Assay in a 25- $\mu$ L volume. GAPDH was used to normalize all samples. The QPCR data are presented as fold changes in normalized mRNA levels in control versus experimental samples and are the average of at least triplicate experiments with SEM presented as error bars.

### Transfections and luciferase assays

The reporter plasmids PPAR response element (PPRE; 3  $\mu$ g) and *Spry4* promoter-luciferase (3  $\mu$ g; kindly provided by Dr. Warburton, University of Southern California, Los Angeles, CA), expression plasmids wild-type PPAR $\gamma$  (3  $\mu$ g) and *Spry4* (3  $\mu$ g), and  $\beta$ -galactosidase control

plasmids (3  $\mu$ g) were transfected into H157 and H2122 cells using Lipofectamine Reagent (Invitrogen). Truncated Spry4 luciferases were constructed from the full-length promoter luciferase (-4,446) at -1,182, -418, and -31 bp from the transcription start site. Truncated Spry4 luciferases -4,446, -1,182, and -418 were gifts from Dr. Warburton (29), and the -31 luciferase was constructed by the University of Colorado Denver Diabetes and Endocrinology Research Center Molecular Biology Core. PPAR $\gamma$  inhibitor T0070907 (Cayman Chemical) was applied once at 25  $\mu$ mol/L 24 hours after transfection. Cells were collected, washed with PBS, and resuspended in Luciferase Reporter Lysis Buffer (Promega). After centrifugation, luciferase activity was measured in the supernatant using a Luciferase Assay (Promega) and  $\beta$ -galactosidase activity was measured by absorbance.  $\beta$ -Galactosidase was used for normalization. The data are presented as fold change in relative light units per milliunits of  $\beta$ -galactosidase and represent the average of three independent experiments.

### Immunoblot analysis

The following antibodies were used for immunoblotting: Spry4 and Survivin (Santa Cruz Biotech), Wnt7A (R&D Systems), E-cadherin (Cell Signaling), GAPDH, CD82, and  $\beta$ -actin (Abcam). Cell extracts for all immunoblots were prepared in a MAPK lysis buffer. Aliquots of lysates were resolved by 10% SDS-PAGE and transferred to nitrocellulose. The membranes were blocked in TBS with 3% bovine serum albumin and then incubated with primary antibody for 12 to 16 hours at 4°C. Membranes were washed in TBS, incubated with alkaline phosphatase-coupled secondary antibodies for 1 hour at 4°C, and visualized with LumiPhos reagent (Pierce).  $\beta$ -Actin or GAPDH were used as loading controls.

### Three-dimensional cell culture, collagen invasion assay, and scratch assay

Three-dimensional basement membrane cultures were established as previously described (30). Briefly, 5,000 cells per well were grown in 2% Matrigel (BD Bioscience) with EGF on a 50% Matrigel base layer. The collagen invasion assay was done as previously described (31). Briefly, 5,000 cells per well were seeded in 2% Matrigel on a layer of 1:1 collagen (BD Bioscience) to Matrigel mix. Culture growth recorded on day 5. For the scratch assay, cells were grown in complete growth medium until 90% to 100% confluent. A 3-mm space was introduced across the diameter of each plate. At time zero, cells were treated with 1  $\mu$ g/mL mitomycin to inhibit cell proliferation. Cell migration was recorded at 24 and 48 hours. Images were captured using a  $\times$ 40 lens on a light microscope and a digital camera.

### Matrix metalloproteinase-9 activity assay


The matrix metalloproteinase-9 (MMP-9) Human Bio-trak assay (GE Healthcare) was used to measure the levels of active MMP-9 in NSCLC cell lines. Briefly, the assay used 100  $\mu$ L of cell culture supernatant, a two-site ELISA sandwich format to measure the endogenous levels of

active MMP-9 relative to a set of standards. Absorbance was measured at 405 and is presented as fold change in active MMP-9 levels interpolated from the standard curve.

## Results

### Spry4 expression is lost in NSCLC cell lines

Sixteen NSCLC cell lines were analyzed by QPCR, and decreased Spry4 expression was detected in 21 cell lines relative to the nontransformed human lung epithelial cell line HBEC (the HBEC cell line was cultured in a different media than the NSCLC cell lines; Fig. 1A). Eleven of 11 dysplastic lung cell cultures analyzed for Spry4 expression also had




**FIGURE 1.** Spry4 expression is decreased in NSCLC cell lines and dysplastic lung cell culture. A and B, QPCR for Spry4 mRNA in NSCLC cell lines and dysplastic lung epithelial cell culture. Dysplastic cell cultures are arbitrarily numbered 3 to 13. Cell line mRNA levels are presented as fold reductions compared with the nontransformed lung epithelial cell line HBEC. Results are the average of triplicate experiments normalized to GAPDH. C, immunoblot (IB) analysis of Spry4 protein expression in NSCLC cell lines compared with a nontransformed lung epithelial cell line (HBEC).  $\beta$ -Actin is included as a loading control.

reduced levels of mRNA compared with B2B and HBEC cells (Fig. 1B). In Fig. 1C, immunoblot data for NSCLC cell lines H157, H2122, A549, H661, and H1703, and the HBEC cell line show reduced expression of *Spry4* in NSCLC cell lines compared with the nontransformed cell line.

### Wnt7A/Fzd9 signaling increases *Spry4* promoter activity through PPAR $\gamma$ in NSCLC


PPAR $\gamma$  activation leads to the suppression of growth and the restoration of epithelial differentiation in NSCLC and has been identified as a mediator of Wnt7A/Fzd9 tumor suppression signaling (18, 20). Previous data indicate that *Spry4* expression is increased in response to Wnt7A/Fzd9 pathway activation, indicating that both PPAR $\gamma$  and *Spry4* are downstream targets of Wnt7A/Fzd9 (17). We have previously described H157 and H2122 cell lines as lacking Wnt7a/Fzd9 and Fzd9, respectively, and have generated

cell lines with stable Wnt7a and/or Fzd9 expression (17). We transfected *Spry4*-luciferase into H157 and H2122 cells with stable Wnt7A and/or Fzd9 expression. In both cell lines, the establishment of the Wnt7A/Fzd9 signaling pathway led to increased *Spry4*-luciferase activity (Fig. 2A). To establish the relationship between PPAR $\gamma$  and *Spry4*, H157 and H2122 cells were transiently transfected with empty vector, *Spry4*, or wild-type PPAR $\gamma$ , along with a vector encoding a PPRE luciferase or a *Spry4* promoter luciferase. In H157 and H2122 cells, the expression of *Spry4* did not lead to increased PPRE luciferase activity (Fig. 2B). Transfection of PPAR $\gamma$  into H157 and H2122 cells with or without T0070907 (T007), a PPAR $\gamma$  inhibitor, showed increased *Spry4* luciferase activity with wild-type PPAR $\gamma$  and decreased activity with T007 treatment (Fig. 2B). PPAR $\lambda$  did not activate the *Spry4* luciferase (data not shown). To further connect PPAR $\gamma$  expression with *Spry4* promoter



**FIGURE 2.** The *Spry4* promoter is activated by PPAR $\gamma$  expression. A, H157 and H2122 cells with stable Wnt7A and/or Fzd9 expression were transfected with *Spry4*-luciferase. Results are the average of triplicate experiments. B, H157 and H2122 cells were transiently transfected with PPRE-luc, *Spry4*, and wild-type (WT) PPAR $\gamma$ . H157 and H2122 cells were transfected with wild-type PPAR $\gamma$  and *Spry4* promoter luciferase, and treated with T007, a PPAR $\gamma$  inhibitor. Results are the average of triplicate experiments. C, H157 and H2122 cells with stable PPAR $\gamma$  expression were transfected with full-length (-4,446) and truncated versions of *Spry4*-luciferase (-1,182, -418, and -31). Results are the average of triplicate experiments. Change in activity is presented as fold induction of the luciferase reporter.





**FIGURE 3.** Stable expression of Spry4 reduces cell growth and anchorage-independent growth in NSCLC cells. **A**, stable Spry4 expression in transfected H157 and H2122 cells was verified by immunoblot with a GAPDH loading control and by QPCR. **B**, 50,000 cells from H157 and H2122 stably expressing Spry4 or an empty vector control were plated in triplicate in six-wells, and one well was counted each day. Results are the average of triplicate experiments. **C**, 25,000 cells from H157 and H2122 stably expressing Spry4 or an empty vector control were seeded in triplicate in media with 0.3% agar on a base of 0.5% agar. Colonies were stained with nitroblue tetrazolium chloride at 21 d. Representative soft agar pictures are shown. Cloning efficiency is the ratio of counted colonies to seeded cells and is the average of triplicate experiments. **D**, QPCR for p21 and p53 in H2122 cell lines stably expressing Spry4 compared with an empty vector control. Results are the average of triplicate experiments normalized to GAPDH.

activity, H157 and H2122 cells with stable expression of PPAR $\gamma$  were transfected with full-length (-4,446) or one of the three truncated Spry4 promoter luciferases (-1,182, -418, and -31; Fig. 2C). Activity of the Spry4 promoter decreased with sequences smaller than the 1,182 truncation, suggesting that a sequence between 1,182 and 31 bp from the transcription start site in the promoter is needed for the influence of PPAR $\gamma$  on Spry4 promoter activity.

#### Spry4 reexpression in NSCLC reduces cell growth and colony formation in soft agar and increases expression of tumor suppressors

Wnt7A/Fzd9 signaling through PPAR $\gamma$  has been shown to inhibit NSCLC cell growth and reduce colony formation

in soft agar (17). We were interested whether Spry4 contributes to the growth suppression effects of Wnt7A/Fzd9. The role of Spry4 on NSCLC growth was assessed using H157 and H2122 cells stably transfected with Spry4 or an empty vector. Stable expression of Spry4 was confirmed by immunoblot and QPCR (Fig. 3A). To investigate the influence of Spry4 on transformed cell growth, equal numbers of H157 and H2122 cells with Spry4 reexpression or empty vector control were plated in complete medium, and cell numbers were measured for 6 days. Expression of Spry4 significantly reduced the growth rate of H157 and H2122 cells compared with empty vector control cells (Fig. 3B). Soft agar assays were used to evaluate the effect of Spry4 expression on colony formation, in which transformed cells are able to

grow in an anchorage-independent manner but nontransformed cells are not. After 21 days of observation, stable expression of Spry4 inhibited colony formation compared with empty vector control cells (Fig. 3C). Apoptotic activity was evaluated in the context of Spry4 expression, and there was no difference in caspase-3/7 activity or Survivin protein level when compared with empty vector control cells (data not shown). To identify possible downstream targets of Spry4, QPCR was used to analyze the mRNA expression of p53 and p21 in H2122 cells with Spry4 reexpression. p53 and p21 were increased with Spry4 expression compared with an empty vector control (Fig. 3D). p53 and its target p21 are well-known members of tumor suppression pathways in the lung (32). Increased expression of these genes may be related to the inhibition of proliferation observed with Spry4 reexpression. These results show that Spry4 expression reduces cell growth and anchorage-independent growth, two key characteristics of transformed cells.


### Spry4 reexpression promotes a mesenchymal to epithelial transition

Because Spry4 expression was increased by PPAR $\gamma$ , we evaluated the effect of Spry4 on the induction of epithelial differentiation. H157 and H2122 cells with stable Spry4 expression were grown in a three-dimensional culture and were observed for 5 days. Cell lines expressing Spry4 exhibited a change in morphologic architecture compared with cell lines expressing the empty vector, demonstrated by the restoration of an organized, spherical structure (Fig. 4A). E-cadherin is known to regulate the maintenance of an epithelial phenotype (33). Previous data have shown that E-cadherin is upregulated by Wnt7A/Fzd9 signaling and is involved in the maintenance of an epithelial phenotype (18). Immunoblot data showed that the expression of Spry4 leads to increased E-cadherin protein expression in H157 and H2122 cell lines compared with empty vector controls (Fig. 4B). In the context of Spry4 expression, markers of an epithelial state, KRT8 and KRT18, were increased by QPCR, whereas Vimentin, a marker of mesenchymal state, was decreased (Fig. 4C). These data suggest that Spry4 is involved in promoting the epithelial differentiation stimulated by Wnt7A/Fzd9 signaling.


### Spry4 reduces migration and invasion in NSCLC and reduces MMP-9 activity

Spry4 has been observed to inhibit migration in prostate, pancreatic cells, and endothelial cells, but effects of Spry4 on NSCLC migration and invasion have not been investigated (7, 34, 35). To assess the effects of Spry4 on cell motility, we performed a scratch assay. A 3-mm space was created on confluent plates of H157 and H2122 cells expressing Spry4 or the empty vector. Cells were treated at time zero with 1  $\mu$ g/mL mitomycin to inhibit proliferation, and the experiment was conducted in triplicate. The cells were photographed at 24 and 48 hours to record the movement of cells into the space created by the lesion. H157 and H2122 cells expressing Spry4 exhibited reduced motility compared with empty vector-transfected cell lines

(Fig. 5A). Invasiveness of cells with stable Spry4 expression was examined using a three-dimensional collagen/Matrigel matrix, as depicted in Fig. 5B. In a chambered glass slide, a layer of 1:1 collagen to Matrigel was applied, followed by a mix of cells, media, and Matrigel (31). Photographs of cells



**FIGURE 4.** Spry4 reexpression induces a more epithelial phenotype in NSCLC cells. A, 5,000 cells from H157 and H2122 stably expressing Spry4 or an empty vector control were seeded in media with 4% Matrigel on top of a 1:1 Matrigel and media base layer. Cell morphology was recorded on day 5. Data are representative of triplicate experiments. B, Western blot analysis of E-cadherin in cell lysates from H157 and H2122 cell lines with stable Spry4 expression compared with an empty vector control. Loading control is  $\beta$ -actin, and data are representative of triplicate experiments. C, QPCR for KRT8, KRT18, and Vimentin in H157 and H2122 cell lines stably expressing Spry4 compared with an empty vector control. Results are the average of triplicate experiments and are normalized to GAPDH.



**FIGURE 5.** Reexpression of Spry4 inhibits migration and invasion in NSCLC cells. **A**, a 3-mm space was created across the diameter of plates of H157 and H2122 cells stably expressing Spry4 or an empty vector control, and migration was recorded at 24 and 48 h. Results are representative of triplicate experiments. **B**, the three-dimensional invasion assay uses a layer of collagen beneath a layer of Matrigel and media containing the cells of interest. Five thousand cells from H157 and H2122 stably expressing Spry4 or an empty vector control were seeded in triplicate in media with 4% Matrigel on top of a 1:1 Matrigel and collagen base layer. Cell invasion was recorded on day 5. **C**, expression levels of CD82 and TIMP1 were assessed by QPCR in H157 and H2122 cell lines stably expressing Spry4 or an empty vector control. Results are the average of triplicate experiments normalized to GAPDH. **D**, increased expression of CD82 was confirmed by Western blot analysis of cell lysates from H157 and H2122 cell lines stably expressing Spry4 compared with an empty vector control. Loading control is  $\beta$ -actin. **E**, H157 and H2122 cells stably expressing Spry4, and corresponding empty vector controls were seeded in a 96-well plate and analyzed with the MMP-9 Human Biotrak Assay. Absorbance was measured, and a standard curve was used to calculate the amount of active MMP-9 in the samples. Results are the average of triplicate experiments with SEM.

were taken from above the wells, where cell extensions into the lower collagen layer can be observed. After 5 days of growth, Spry4-expressing cell lines showed reduced invasion into the collagen/Matrigel matrix compared with empty vector-transfected cell lines (Fig. 5B). The reduction of cell mobility and invasion shown with Spry4 expression suggests that Spry4 may act on downstream targets to inhibit metastasis.

We were also interested in previously unidentified targets of Spry4 that might be related to migration or invasion.

CD82 is a tetraspanin cell surface glycoprotein identified based on its function as a migration suppressor independent of tumor growth and has been identified as a marker of good prognosis in NSCLC (36, 37). We were interested in a possible role for CD82 in the inhibition of migration and invasion observed with Spry4 reexpression. Spry4 expression resulted in increased CD82 mRNA levels and increased CD82 protein expression by immunoblot (Fig. 5C and D). CD82 mRNA expression was decreased by QPCR in 11 NSCLC cell lines compared with nontransformed B2B

cell line (data not shown). Nine of those cell lines also had decreased expression of Spry4 compared with B2B, suggesting a correlation between reduced levels of CD82 and Spry4. CD82 has been associated with reduced MMP-9 protein and enzymatic activity in NSCLC (38). Levels of active MMP-9 were assayed using an ELISA kit and were found to be decreased in Spry4 stably expressing H157 and H2122 cells compared with empty vector controls (Fig. 5E). Reduced activity of MMP-9 was also observed in the H157 cell line with reexpressed Wnt7A and Fzd9 (data not shown). TIMP1, a negative regulator of MMP-9, was upregulated by QPCR and has been suggested as the link between CD82 and decreased MMP-9 activity (Fig. 5C; ref. 38). These targets of Spry4 may be responsible for the reduction of migration and invasion that was observed with Spry4 reexpression.


### Knockdown of Spry4 expression by shRNA leads to reversed expression of epithelial to mesenchymal transition markers and increased cell growth

To assess the effects of loss of Spry4 expression on a non-transformed lung epithelial cell line, B2B cells were stably transfected with shRNA or an shRNA-negative control. Reduction of Spry4 expression was confirmed by immunoblot and QPCR (Fig. 6A and B). Expression of Spry4 shRNA led to the decreased expression of epithelial mar-

kers KRT8 and KRT18, decreased expression of migration suppressor CD82, and decreased expression of growth suppressors p53 and p21 (Fig. 6B). Increased expression of mesenchymal marker Vimentin was also observed with Spry4 knockdown (Fig. 6B). In a cell growth assay, loss of Spry4 expression by shRNA led to increased cell growth of B2B cells compared with a negative control (Fig. 6C). Increased cell growth was observed by an MTS cell proliferation assay when Spry4 expression was knocked down by shRNA in H157 and H2122 cell lines stably expressing Wnt7a/Fzd9 (Fig. 6D). In the context of Wnt7a/Fzd9 expression in lung epithelial cells, Spry4 expression is important for the inhibition of cell growth. These data suggest that the loss of Spry4 expression in lung epithelial cells could be one step leading to transformation or increased migration and invasion.


### Discussion

In this study, we were interested in identifying regulators and targets of Spry4 in NSCLC, about which little was previously known. In a noncanonical Wnt signaling pathway, Wnt7A and Fzd9 have previously been shown to act in a tumor-suppressive manner to reduce cell growth and promote epithelial cell differentiation in NSCLC (17). Wnt7A/Fzd9 activates PPAR $\gamma$  through an ERK5-dependent pathway and signals to downstream



**FIGURE 6.** Treatment of a nontransformed lung epithelial cell line, Beas2B (B2B), with shRNA to Spry4 leads to changes in epithelial to mesenchymal transition markers and increased cell growth. A, immunoblot for expression of Spry4 and E-cadherin in B2B cells treated with shRNA to Spry4. Loading control is  $\beta$ -actin. B, QPCR was used to measure Spry4, KRT8, KRT18, CD82, p53, p21, and Vimentin mRNA levels in B2B cells treated with Spry4 shRNA. Results are the average of triplicate experiments normalized to GAPDH. C, 20,000 cells from B2B cells treated with shRNA to Spry4 or an shRNA control were plated in six-wells, and one well was counted each day. Data shown are the average of triplicate experiments. D, 500 cells from each cell line were seeded per well in triplicate. At 24, 48, and 72 h, 20  $\mu$ L of MTS reagent (Promega) were added to each well, incubated for 1 h at 37°C, and analyzed at 490 nm. Results are presented as the average of triplicate experiments.





**FIGURE 7.** A model for Wnt7A/Fzd9 activation of Spry4 through PPAR $\gamma$ . Expression of Spry4 results in decreased MMP-9 activity, through CD82 and TIMP1, and increased E-cadherin, p21, and p53 expression.

targets such as E-cadherin (18). Based on our study, Spry4 seems to act as a tumor suppressor in NSCLC. Spry4 promoter activity is increased by PPAR $\gamma$ , a downstream target of Wnt7A/Fzd9 signaling, and affects cell growth, differentiation, motility, and invasion. Figure 7 depicts our proposed signaling model for the Wnt7a and Spry4 pathway. The identification of changes in the expression of genes known to be important in tumor suppression, differentiation, metastasis, and invasion supports the biological effects observed with Spry4 reexpression. Of potential clinical significance is our observation that Spry4 is frequently lost in NSCLC and dysplastic lung epithelial cells.

The regulation of Spry4 expression is still largely undetermined. Tyrosine phosphorylation induced by growth factors has been identified as a positive regulator of Spry, although the phosphorylation is specific to cell type, growth factor, and individual Spry (39). Spry4 can be induced by FGF, EGF, and platelet-derived growth factor, but unlike Spry1 and Spry2, it does not seem to be phosphorylated in response to growth factor treatment (39, 40). However, the phosphorylation of mouse Spry4 at Tyr<sup>53</sup> is required for the inhibition of FGF-induced ERK activation (27). We have shown that the reintroduction of the Wnt7A/Fzd9 signaling pathway in NSCLC cell lines leads to the increased activity of the Spry4 promoter. Loss of Spry4 expression by shRNA in cell lines with stable Wnt7a/Fzd9 expression led to increased cell growth, further strengthening the signaling link between Wnt7A and Spry4. Our data also show that Spry4 is regulated by PPAR $\gamma$  signaling, a novel mode of regulation of Spry4 expression outside of the RTK pathway. We have shown that truncation of the Spry4 promoter leads to reduced activation of Spry4-luc in PPAR $\gamma$ -expressing cell lines; however, no consensus site for PPAR $\gamma$  exists within the promoter region. There is one-half DR1 binding site near -1,600 bp, but its functionality is unknown. Analysis

of the Spry4 promoter region has identified many transcription factor binding sites, suggesting complicated regulation of the Spry4 promoter (29). In our study, the observation of a more gradual decrease in activity, as opposed to a drastic change with a single truncation, suggests that there may be multiple factors working in collaboration to regulate the Spry4 promoter. Further functional analysis is required to determine the regulatory connection between PPAR $\gamma$  and Spry4.

Inhibition of FGF-induced activation of the ERK pathway by Spry4 can occur through binding with Sos1 and is enhanced by heterodimerization with Spry1 (41). In the vascular endothelial growth factor pathway, Spry4 can bind to Raf1 and inhibit Ras-independent inhibition of ERK activation (5). Spry4 has been shown to interact with testicular protein kinase 1 and lead to the inhibition of integrin-mediated cell spreading (42). Beyond these examples, the targets of Spry4 are largely unknown. We have shown that Spry4 reexpression leads to increased expression of tumor suppressors p53 and p21. p53 is a well-known negative growth regulator and is frequently lost in NSCLC (43). p21 negatively regulates cell cycle progression, and loss of p21 results in the failure of cells to undergo cell cycle arrest in response to p53 activation (44). Upregulation of these tumor suppressors may be related to the observed decrease in cell proliferation and anchorage-independent growth with Spry4 expression.

We observed increased expression of CD82 and TIMP1, and decreased active MMP-9 levels in cells expressing Spry4. We have also observed that active MMP-9 is decreased in H157 cells with stable Wnt7A/Fzd9 expression, although not as significantly. This provides further evidence of a signaling link between Spry4 and Wnt7A. CD82 is ubiquitously expressed in normal tissues and is downregulated in a variety of cancers; in lung cancer, CD82 expression has been associated with good prognosis, and decreased metastasis and invasive potential (36, 37). In an orthotopic lung tumor model, CD82 dramatically reduced lymph node metastases (45). CD82 has been shown to upregulate TIMP1 in NSCLC, leading to the suppression of invasion and metastases by inactivating MMP-9 (38). These previous studies support a role for CD82 in the inhibition of invasion and metastasis in our study. Additionally, the CD82 promoter contains a binding motif for p53, which may act synergistically with junB to induce CD82 promoter activity (46). Increased levels of p53 in our study may be leading to the increased levels of CD82 and, subsequently, decreased migration and invasion.

A mesenchymal to epithelial transition mediated by Wnt7A/Fzd9 may be acting through Spry4 (17). In normal cells, cadherin-dependent contacts between cells promote proper development and maintenance of normal epithelia (33). Epithelial tumor cells gradually lose their normal phenotype and acquire more mesenchymal characteristics, with increased motility and invasion (47). Our findings support a role for Spry4 as a downstream target of Wnt7A/Fzd9 in the mesenchymal to epithelial transition; Spry4 expression induced a more differentiated epithelial

phenotype in a three-dimensional culture; induced expression of E-cadherin, KRT8, and KRT18; and suppressed migration and invasion. It is important to note that although Spry4 is a key mediator of the effects of Wnt7A/Fzd9 pathway, the pathway is known to signal to other targets that play a role in its biological effects (48-50).

Spry proteins have been found to participate in multiple pathways related to RTK signaling, dependent on cellular context and the specific RTK. Sprys have been shown to antagonize the Ras-ERK MAPK pathway by inhibiting the activation of Ras and Raf1 or to agonize EGF-mediated ERK MAPK signaling through an interaction with c-CBL (3). Spry4, however, does not bind c-CBL and, thus, has not been linked to agonist activity (39). EGF receptor inhibition by Spry4 was observed in one study using NIH3T3 cells but not in several other studies (6, 26, 27, 41). In mouse studies, overexpression of Spry4 led to severe pulmonary hypoplasia, and loss of Spry4 led to sustained ERK signaling in response to FGF (26, 51). The canonical Wnt/ $\beta$ -catenin signaling pathway has been shown to interact with FGF signaling at GSK3 $\beta$  (52). However, Wnt7A/Fzd9 signaling does not activate  $\beta$ -catenin signaling, so any interaction with growth factor pathways would occur through an alternate pathway (17, 53). It may be possible that the Wnt7A/Fzd9 pathway is interacting with growth factor signaling pathways through Spry4 in a manner opposite of the canonical Wnt/ $\beta$ -catenin pathway, leading to tumor suppression instead of promotion. Spry4 could also be activated independent of RTK inhibition depending on the context. Studies are necessary to clarify the range of RTK inhibition by Spry4, the effects of possible dimerization between Sprys on RTK inhibition, and the potential interaction between Wnt and growth factor signaling, all in the context of NSCLC.

Loss of Spry4 expression by shRNA in a nontransformed lung epithelial cell line led to increased cell growth and decreased expression of epithelial markers in our

study. These data suggest that Spry4 may influence the transformation of normal lung epithelial cells and may also suppress epithelial to mesenchymal transition in the lung epithelium. Spry4 expression is lost in NSCLC cells and dysplastic lung epithelial cell lines, similar to Wnt7A; however, the timing of loss is unknown (54, 55). Methylation of *Spry4* has been detected in prostate cancer tissue (7). *Wnt5a*, another noncanonical, tumor-suppressing Wnt, is methylated in colorectal cancer and leukemia, suggesting the possibility that *Wnt7A* may also be methylated in NSCLC (56, 57). Further research needs to be done to establish whether loss of Wnt7A and Spry4 expression are early or late events in lung tumorigenesis and what the mechanism of loss is. We have presented data suggesting that Spry4 is downstream of PPAR $\gamma$  in the Wnt7A/Fzd9 tumor suppression pathway, and that it acts to reduce cell growth, inhibit anchorage-independent growth, suppress migration and invasion, and restore a non-transformed epithelial phenotype. Pharmacologic activation of Spry4 may be a future target for treatment of NSCLC.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Grant Support

Merit Award from the U.S. Department of Veterans Affairs, NIH grant #K22CA113700, NIH Specialized Programs of Research Excellence in Lung Cancer program Career Development Award #46345-AEFCCTR, and an NIH T32 Training Grant through the Cardiovascular Pulmonary Program of the University of Colorado Denver. The Spry4 luciferase-31 was constructed by the University of Colorado Denver Diabetes and Endocrinology Research Center Molecular Biology Core: NIH P30DK57516.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 08/31/2009; revised 04/20/2010; accepted 04/28/2010; published OnlineFirst 05/25/2010.

#### References

- Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the *Drosophila* airways. *Cell* 1998;92:253-63.
- Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. *Cell* 1999;96:655-65.
- Mason JM, Morrison DJ, Basson MA, Licht JD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. *Trends Cell Biol* 2006;16:45-54.
- Gross I, Bassit B, Benezra M, Licht JD. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. *J Biol Chem* 2001;276:46460-8.
- Sasaki A, Taketomi T, Kato R, et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. *Nat Cell Biol* 2003;5:427-32.
- Leeksa OC, Van Achterberg TA, Tsumura Y, et al. Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. *Eur J Biochem* 2002;269:2546-56.
- Wang J, Thompson B, Ren C, Iltmann M, Kwabi-Addo B. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. *Prostate* 2006;66:613-24.
- Lo TL, Fong CW, Yusoff P, et al. Sprouty and cancer: the first terms report. *Cancer Lett* 2006;242:141-50.
- Minowada G, Miller YE. Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis. *Am J Respir Cell Mol Biol* 2009;40:31-7.
- Sutterluty H, Mayer CE, Setinek U, et al. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. *Mol Cancer Res* 2007;5:509-20.
- Shaw AT, Meissner A, Dowdle JA, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. *Genes Dev* 2007;21:694-707.
- Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. *Biochim Biophys Acta* 2003;1653:1-24.
- Howe LR, Brown AM. Wnt signaling and breast cancer. *Cancer Biol Ther* 2004;3:36-41.
- Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between  $\beta$ -catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. *Mol Cancer* 2008;7:21.

15. Dahl C, Gulberg P. The genome and epigenome of malignant melanoma. *APMIS* 2007;115:1161–76.
16. Suzuki H, Toyota M, Caraway H, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. *Br J Cancer* 2008;98:1147–56.
17. Winn RA, Marek L, Han SY, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. *J Biol Chem* 2005;280:19625–34.
18. Winn RA, Van Scoyk M, Hammond M, et al. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor  $\gamma$ . *J Biol Chem* 2006;281:26943–50.
19. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. *Nat Rev Cancer* 2004;4:61–70.
20. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA. Peroxisome proliferator-activated receptor- $\gamma$  (PPAR  $\gamma$ ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). *Oncogene* 2005;24:1412–22.
21. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor- $\gamma$  agonists through induction of apoptosis. *Biochem Biophys Res Commun* 2000;270:400–5.
22. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor  $\gamma$  in non-small cell lung cancer. *Cancer Res* 2000;60:1129–38.
23. Leung WK, Bai AH, Chan VY, et al. Effect of peroxisome proliferator activated receptor  $\gamma$  ligands on growth and gene expression profiles of gastric cancer cells. *Gut* 2004;53:331–8.
24. Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor  $\gamma$  ligand, on the growth of human ovarian cancers. *Cancer* 2007;110:791–800.
25. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor  $\gamma$  ligands suppress colon carcinogenesis induced by azoxymethane in mice. *Gastroenterology* 2003;124:361–7.
26. Taniguchi K, Ayada T, Ichiyama K, et al. Sprouty2 and Sprouty4 are essential for embryonic morphogenesis and regulation of FGF signaling. *Biochem Biophys Res Commun* 2007;352:896–902.
27. Sasaki A, Taketomi T, Wakioka T, Kato R, Yoshimura A. Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor- but not epidermal growth factor-induced ERK activation. *J Biol Chem* 2001;276:36804–8.
28. Zhang S, Lin Y, Itaranta P, Yagi A, Vainio S. Expression of Sprouty genes 1, 2 and 4 during mouse organogenesis. *Mech Dev* 2001;109:367–70.
29. Ding W, Bellusci S, Shi W, Warburton D. Genomic structure and promoter characterization of the human Sprouty4 gene, a novel regulator of lung morphogenesis. *Am J Physiol Lung Cell Mol Physiol* 2004;287:L52–9.
30. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 2003;30:256–68.
31. Xiang B, Muthuswamy SK. Using three-dimensional acinar structures for molecular and cell biological assays. *Methods Enzymol* 2006;406:692–701.
32. Coopman PJ, Mueller SC. The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. *Cancer Lett* 2006;241:159–73.
33. Acloque H, Thiery JP, Nieto MA. The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. *EMBO Rep* 2008;9:322–6.
34. Lee SH, Schloss DJ, Jarvis L, Krasnow MA, Swain JL. Inhibition of angiogenesis by a mouse sprouty protein. *J Biol Chem* 2001;276:4128–33.
35. Jaggi F, Cabrera MA, Perl AK, Christofori G. Modulation of endocrine pancreas development but not  $\beta$ -cell carcinogenesis by Sprouty4. *Mol Cancer Res* 2008;6:468–82.
36. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. *Cancer Lett* 2006;240:183–94.
37. Tonoli H, Barrett JC. CD82 metastasis suppressor gene: a potential target for new therapeutics? *Trends Mol Med* 2005;11:563–70.
38. Jee BK, Park KM, Surendran S, et al. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. *Biochem Biophys Res Commun* 2006;342:655–61.
39. Mason JM, Morrison DJ, Bassit B, et al. Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. *Mol Biol Cell* 2004;15:2176–88.
40. Ozaki K, Kadomoto R, Asato K, Tanimura S, Itoh N, Kohno M. ERK pathway positively regulates the expression of Sprouty genes. *Biochem Biophys Res Commun* 2001;285:1084–8.
41. Ozaki K, Miyazaki S, Tanimura S, Kohno M. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. *J Cell Sci* 2005;118:5861–71.
42. Tsumura Y, Tushima J, Leeksa OC, Ohashi K, Mizuno K. Sprouty-4 negatively regulates cell spreading by inhibiting the kinase activity of testicular protein kinase. *Biochem J* 2005;387:627–37.
43. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. *Oncogene* 2002;21:6898–907.
44. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. *Cancer Res* 2005;65:3980–5.
45. Takeda T, Hattori N, Tokuhara T, Nishimura Y, Yokoyama M, Miyake M. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. *Cancer Res* 2007;67:1744–9.
46. Marreiros A, Dudgeon K, Dao V, et al. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. *Oncogene* 2005;24:637–49.
47. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. *Biochem Pharmacol* 2000;60:1091–9.
48. Xu Y, Farmer SR, Smith BD. Peroxisome proliferator-activated receptor  $\gamma$  interacts with CIITA x RFX5 complex to repress type I collagen gene expression. *J Biol Chem* 2007;282:26046–56.
49. Bren-Mattison Y, Meyer AM, Van Putten V, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor- $\gamma$  in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor- $\kappa$ B. *Mol Pharmacol* 2008;73:709–17.
50. Lee SY, Hur GY, Jung KH, et al. PPAR- $\gamma$  agonist increase gefitinib's antitumor activity through PTEN expression. *Lung Cancer* 2006;51:297–301.
51. Perl AK, Hokuto I, Impagnatiello MA, Christofori G, Whittsett JA. Temporal effects of Sprouty on lung morphogenesis. *Dev Biol* 2003;258:154–68.
52. Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3 $\beta$  to regulate  $\beta$ -catenin and SNAIL signaling cascades. *Cancer Biol Ther* 2006;5:1059–64.
53. Karasawa T, Yokokura H, Kitajewski J, Lombroso PJ. Frizzled-9 is activated by Wnt-2 and functions in Wnt/ $\beta$ -catenin signaling. *J Biol Chem* 2002;277:37479–86.
54. Calvo R, West J, Franklin W, et al. Altered HOX and WNT7A expression in human lung cancer. *Proc Natl Acad Sci U S A* 2000;97:12776–81.
55. Kirikoshi H, Katoh M. Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. *Int J Oncol* 2002;21:895–900.
56. Ying J, Li H, Yu J, et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/ $\beta$ -catenin signaling, and is frequently methylated in colorectal cancer. *Clin Cancer Res* 2008;14:55–61.
57. Roman-Gomez J, Jimenez-Velasco A, Cordeu L, et al. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. *Eur J Cancer* 2007;43:2736–46.

# Molecular Cancer Research

## Sprouty-4 Inhibits Transformed Cell Growth, Migration and Invasion, and Epithelial-Mesenchymal Transition, and Is Regulated by Wnt7A through PPAR $\gamma$ in Non-Small Cell Lung Cancer

Meredith A. Tennis, Michelle M. Van Scoyk, Scott V. Freeman, et al.

*Mol Cancer Res* 2010;8:833-843. Published OnlineFirst May 25, 2010.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1541-7786.MCR-09-0400](https://doi.org/10.1158/1541-7786.MCR-09-0400)

**Cited articles** This article cites 57 articles, 20 of which you can access for free at:  
<http://mcr.aacrjournals.org/content/8/6/833.full.html#ref-list-1>

**Citing articles** This article has been cited by 5 HighWire-hosted articles. Access the articles at:  
</content/8/6/833.full.html#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).